Asset Management One Co. Ltd. Raises Holdings in Edwards Lifesciences Corporation $EW

Asset Management One Co. Ltd. grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 3.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 269,353 shares of the medical research company’s stock after buying an additional 9,604 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Edwards Lifesciences were worth $23,410,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Viking Global Investors LP bought a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $238,688,000. Jennison Associates LLC increased its position in Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Bank of New York Mellon Corp increased its position in Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in Edwards Lifesciences by 114.5% during the 3rd quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock valued at $161,055,000 after buying an additional 1,111,139 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the transaction, the vice president owned 33,934 shares in the company, valued at $2,747,975.32. The trade was a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 86,058 shares of company stock worth $7,118,636. Corporate insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on EW shares. Robert W. Baird set a $90.00 price objective on Edwards Lifesciences in a research report on Monday, January 12th. Barclays reaffirmed an “overweight” rating and set a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, February 11th. The Goldman Sachs Group reissued a “buy” rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Wells Fargo & Company lifted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $95.74.

Edwards Lifesciences Stock Performance

EW stock opened at $81.02 on Monday. The company has a market cap of $46.71 billion, a P/E ratio of 44.27, a price-to-earnings-growth ratio of 2.11 and a beta of 0.95. Edwards Lifesciences Corporation has a 1 year low of $68.63 and a 1 year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The stock’s fifty day moving average price is $81.28 and its 200-day moving average price is $82.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.